Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.

MLA

Wu C.-Y., et al. Phase IA/IB Study of Single-Agent Tislelizumab, an Investigational Anti-PD-1 Antibody, in Solid Tumors. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305132898&authtype=sso&custid=ns315887.

APA

Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., Jameson M., Hou M.-M., Kang Y.-K., Markman B., Lu C.-H., Rau K.-M., Lee K.-H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., … Chao Y. (2020). Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.

Chicago

Wu C.-Y., Zhang Y., Liang L., Wu J., Paton V., Millward M., Keam B., et al. 2020. “Phase IA/IB Study of Single-Agent Tislelizumab, an Investigational Anti-PD-1 Antibody, in Solid Tumors.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305132898&authtype=sso&custid=ns315887.